Updates are available Correction dated 2023-08-09
Click to view Correction: https://doi.org/10.1007/s10620-023-08050-9
-
Authors
Mayo, Marlyn J.
Carey, Elizabeth
Smith, Helen T.
Mospan, Andrea R.
McLaughlin, Megan
Thompson, April
Morris, Heather L.
Sandefur, Robert
Kim, W. Ray
Bowlus, Christopher
,
Ankoma-Sey, Victor
Bernstein, David
Borg, Brian
Bowlus, Christopher
Brown, Robert
Carey, Elizabeth
Clark, Virginia
Darling, Jama
Dranoff, Jonathan
Elbeshbeshy, Hany
Forman, Lisa
Goel, Aparna
Hanje, James
Harrison, Stephen
Janardhan, Sujit
Jesudoss, Randhir
Kim, David
King, Lindsay
Landis, Charles
Levy, Cynthia
Lok, Anna
Lucey, Michael
Luketic, Velmir
Manch, Richard
Mark, Wong
Mayo, Marlyn
Mena, Edward
Modi, Apurva
Reddy, Gautham
Reddy, K. Rajender
Rochling, Fedja
Rojter, Sergio
Rubin, Raymond
Russo, Mark
Shiffman, Mitchell
Silveira, Marina
Stanca, Carmen
Thuluvath, Paul
Verna, Elizabeth
Weiss, L. Michael
Levy, Cynthia http://orcid.org/0000-0001-5498-6037
-
Funding
Funding for this research was provided by:
GlaxoSmithKline (213259)
- License Information
-
More Information
Article History
Received: 2 January 2022
Accepted: 23 May 2022
First Online: 15 June 2022
Change Date: 9 August 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10620-023-08050-9
Declarations
:
: MJM has research funding from TARGET PharmaSolutions, GlaxoSmithKline, Intercept Pharmaceuticals, CymaBay Pharmaceuticals, Genfit, Mirum, and Mallinckrodt; and consultation fees from TARGET PharmaSolutions, GlaxoSmithKline, CymaBay Pharmaceuticals, and Mallinckrodt. EC and WRK have no conflicts to report. HS and MM are employees of GlaxoSmithKline and hold stocks/shares in the company. AT was an employee of GSK at the time of the study and holds stocks/shares in the company. ARM, HLM, and RS are Target RWE employees. CB has research funding from Gilead Biosciences, Intercept Pharmaceuticals, CymaBay Pharmaceuticals, Takeda Pharmaceuticals, GlaxoSmithKline, BristolMyerSquibb, TARGET Pharmasolutions, Novartis, BiomX, Mirum, Genfit, Pliant, Cara Therapeutics, and Boston Scientific. CL has research funding from Gilead, Intercept, CymaBay, Genfit, GSK, Novartis, High Tide, Zydus, Cara Therapeutics, Mirum, Pliant, and Target PharmaSolutions; consultation fees from CymaBay, Genfit, GSK, Pliant, Mirum, Cara Therapeutics, Escient, Teva, Calliditas, and Intercept; royalties from Up-to-date; and is the Associate Editor for Hepatology, Member of the ABIM Test and Policy committee for transplant hepatology.
